Wednesday, July 8, 2026

pharma · Multiple Myeloma · Not applicable - Healthy volonteers · GPCR

Structure Therapeutics

Structure Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker GPCR. Primary therapeutic focus areas include Multiple Myeloma, Not applicable - Healthy volonteer

601 Gateway Blvd, Suite 900, South San Francisco, California 94080, US HQ
2017 Founded
202 Employees
Public company Type
GPCR · NYSE Ticker
Company details
Status
Public
HQ
601 Gateway Blvd, Suite 900, South San Francisco, California 94080, US
Founded
2017
Employees
202
Programs
13
Drugs
7
Patents
93
Clinical program

Aleniglipron

Phase 2 · small molecule · Obese

Aleniglipron for Obese is a Phase 2 program (small_molecule) at Structure Therapeutics with 1 ClinicalTrials.gov record(s).

← All Structure Therapeutics projects Phase 2 small molecule active

Internal code GSBR-1290-17

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Structure Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Obese
Status
active
Trials
1